• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Camptosar (irinotecan)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Camptosar (irinotecan)

  • Profile

Profile

Contact Information

Contact: Pfizer
Website: https://www.pfizer.com/products/product-detail/camptosar

Currently Enrolling Trials

    Show More

    General Information

    Camptosar (irinotecan) is a topoisomerase inhibitor. 

    Camptosar is specifically indicated for the following:

    • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.
    • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

    Camptosar is supplied as a solution for intravenous injection. Administer Camptosar as a 90-minute intravenous infusion followed by LV and 5-FU. 

    Mechanism Of Action

    Camptosar (Irinotecan) is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Research has suggested that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.

    Side Effects

    Adverse effects associated with the use of Camptosar may include, but are not limited to, the following:

    • nausea
    • vomiting
    • abdominal pain
    • diarrhea 
    • constipation
    • anorexia
    • mucositis
    • neutropenia
    • leukopenia (including lymphocytopenia)
    • anemia
    • thrombocytopenia
    • asthenia
    • pain
    • fever
    • infection
    • abnormal bilirubin
    • alopecia

    The Camptosar drug label comes with the following Black Box Warning: Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt Camptosar and reduce subsequent doses if severe diarrhea occurs. Severe myelosuppression may occur.

    Clinical Trial Results

    The FDA approval of Camptosar was based on three clinical trials enrolling 304 patients. Thirty-nine patients (12.8%) responded, 2 with a complete response and 37 with partial responses. Time to progression was 6 months for those with stable disease and median survival was 9 months with a range of up to nearly 3 years. The most consistent responses were observed in subjects beginning treatment at the recommended 125 mg/m2 starting dose. Of the 193 subjects treated at this dose level, 29 experienced a positive response for an overall response rate of 15%. Response refers to the complete disappearance of a tumor (two of the 29 subjects) or a reduction of its size by at least 50% (27 of the 29 patients).

    Approval Date: 1996-06-01
    Company Name: Pfizer
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing